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Chronic Lymphocytic Leukaemia (CLL) is associated with immune suppression and
susceptibility to infection. CD8+ T cell numbers are increased and demonstrate elevated
expression of PD-1 and impaired function. The mechanisms driving these features of
exhaustion are uncertain but are likely to include chronic immune recognition of tumor
and/or infectious agents. We investigated the number, phenotype and function of total
and virus-specific CD8+ T cells in 65 patients with CLL and 14 patients undergoing
long-term ibrutinib therapy (median 21 months). Ibrutinib substantially reduced the
number of both CD3+ T cells and CD8+ T cells. Importantly, this was associated
with a reduction in PD-1 expression on CD8+ T cells (median 28 vs. 24%; p =
0.042) and 3.5 fold increase in cytokine production following mitogen stimulation.
The influence of ibrutinib on antigen-specific CD8+ T cell function was assessed by
HLA-peptide tetramers and revealed increased IFNγ and TNFα cytokine responses
following stimulation with CMV or EBV peptides together with a 55% reduction in the
frequency of “inflated” virus-specific CD8+ T cells. These findings reveal that long-term
ibrutinib therapy is associated with substantial reversal of T cell exhaustion in B-CLL and
is likely to contribute to the reduced infection risk seen in association with this agent.
Keywords: ibrutinib, chronic lymphocytic leukaemia (CLL), herpes viruses, exhaustion, EBV—epstein-barr virus,
CD8T cells, cytomegalovirus, immunotherapy
INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is associated with marked perturbation of the immune
system. A range of defects in T cell function are observed including impaired proliferation,
cytotoxicity and cytokine production (1). Increased absolute numbers of CD8+ T cells, expanded
populations of oligoclonal memory CD8+ T cells (2) and increased expression of immune
checkpoint receptors including PD-1 also feature (3). The etiology of these abnormalities is unclear
but may include chronic immune stimulation through infection and/or tumour engagement.
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Ibrutinib inhibits Bruton Tyrosine Kinase (BTK) activity
and has transformed CLL management (4). Ibrutinib has also
been confirmed by molecular techniques to irreversibly inhibit
interleukin-2 inducible kinase (ITK). ITK plays an important
but not indispensable role in the CD4+ Th1 and CD8+
T cell activation signaling cascade, contributing to enhanced
proliferation and activation following TCR ligation. In contrast,
its role is pivotal and necessary for CD4+ Th2 polarization and
function. As such, inhibition of ITK by ibrutinib encourages
a skewing towards a Th1 phenotype and has been shown to
advantage CD8+ and Th1T cells, which rely on the redundant
resting lymphocyte kinase (RLK) during ITK inhibition. RLK
is a signaling kinase which is not inhibited by ibrutinib and
provides additional activation of the TCR signaling cascade in
the absence of functional ITK. Data on the impact of ibrutinib-
induced ITK inhibition within CD8+ T cell populations is
currently lacking (5). Understanding the impact of long-term
ibrutinib therapy on immune function is an important question
and analysis of antigen-specific responses is also currently
lacking. Cytomegalovirus (CMV) and Epstein Barr Virus (EBV)
are latent herpesvirus infections which infect the majority of
the population. CMV and EBV are known to cause “memory
inflation,” a term used to describe the expansion of memory
CD8+ T cells directed towards the virus and can arise in healthy
individuals but also in patients with immune suppression. (2).
Expanded populations of CMV-specific CD8+ T cells develop in
patients with CLL that are latently infected with the virus.
T cells are known to be dysfunctional in patients with CLL.
The term cell exhaustion is used to describe a state of T cell
dysfunction that occurs through chronic antigen stimulation and
can arise in the context of chronic viral infection or cancer.
Exhausted T cells are characterized by the presence of multiple
inhibitory receptors, poor proliferation, and cytotoxicity and
impaired cytokine secretion (6). Patients with CLL are known to
have features of T cell exhaustion with co-expression of CD244,
PD-1, and CD160 at high frequencies (1).
Here we examine global and virus-specific T cell phenotype
and function in patients with CLL including patients receiving
ibrutinib therapy for up to 32 months. Decreased PD-1
expression and increased cytokine responses were observed
within the global T cell repertoire following ibrutinib treatment
whilst antigen-specific responses also showed increased
functional activity and correction of the increased frequency of
virus-specific cells.
METHODS
Seventy-nine patients with CLL were recruited [median age 70
(IQR: 63–79)], including 42 patients who had never been treated
and 36 who had received chemo-immunotherapy. Of the 36
patients who had previously been treated, 23 were in remission,
whilst 13 patients developed relapsed/refractory disease and
subsequently were started on ibrutinib therapy, together with 1
patient who was treated with ibrutinib in a front line setting.
The 14 patients being treated with ibrutinib, had received up
to 32 months of therapy at the time of analysis. Samples were
collected immediately prior to starting ibrutinib therapy and
then during a subsequent clinic visit which occurred at least 6
months after starting ibrutinib. All patients included in this study
were still taking the drug daily at the point the last sample was
taken for analysis. Patients characteristics for the total cohort and
patient subgroups can be found in (Supplementary Tables 1–4).
Nineteen healthy donors were recruited for controls [median age
72 (IQR. 66–80)].
Following ficoll preparation, plasma and PBMCs were
extracted, with CMV and EBV serostatus determined by
ELISA and immunofluorescence, respectively (7, 8). DNA
extraction was then performed on PBMC pellets using GenElute
Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich) and
HLA typing was assigned using PCR methodology previously
described (9).
Immunophenotypic Analysis of CMV and
EBV-Specific CD8+ T Cells
Immunophenotyping was undertaken following
APC-conjugated HLA class I tetramer staining of PBMCs
at 37◦C for 15min. Details of the tetramers used can be found
in Supplementary Table 5. Tetramers were conjugated to APC
and a true tetramer response was verified through the lack of
background staining by gating all CD3+ T cells, against CD8+
T cells and using a tetramer negative control. Surface staining
with the following antibodies was then performed: live/dead
blue dye (Invitrogen), anti-CD8 Amcyan (BD Biosciences),
anti-CD3 APC-Cy7 (Biolegend), anti-PD-1 PercpCy5.5 (BD
Biosciences), anti-CTLA4 PE-Cy7, anti-CD244 FITC, and
anti-CD160 PE (Biolegend) before washing and flow cytometric
analysis. Memory subset analysis utilized the same panel but
included anti-CCR7 FITC (R&D systems) and anti-CD45RA
AF700 (Biolegend) and omitted anti-CTLA4, anti-CD244, and
anti-CD160. Example flow plots can be found in (Figure S1).
Peptide Stimulation Assays
Following identification of CMV positive and negative donors,
2 × 106 cells were incubated at 37◦C for 5 h with either
PMA and ionomycin, CMV peptide mix (10) or EBV
peptide mix at 10µg/ml (Supplementary Table 6), along with
protein cocktail inhibitor mix (eBiosciences). Live/dead red
dye (Invitrogen), anti-CD3 APC-Cy7 (Biolegend) anti-CD8
Amcyan (BD Biosciences), were then applied before fixation
and permeabilisation and IFN-γ AF700 (Biolegend) and TNF-α
PE-Cy7 staining (eBioscience). Example flow plots can be
found in supplementary (Figure S1). For assessing immune
cell activation and cytotoxic degranulation, 2 × 106 cells were
stimulated with either the above peptide mixes overnight at 37◦C
or a cell stimulation cocktail (Invitrogen) for 5 h. At the time
of stimulation, CD107a FITC (Biolegend), along with brefeldin
A and monensin was incorporated into the stimulation panel
(example staining of CD107a can be found in supplementary).
Statistical Analysis
Mann-Whitney or Kruskal-Wallis testing for comparisons and
multiple regression models were performed.
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RESULTS
Amongst untreated patients (n = 42), and those previously
treated with chemo-immunotherapy only (n = 23), 18.3% of
CD8+ T cells expressed PD-1, an increased frequency compared
to healthy age-matched donors (10.8%; p= 0.0001) (Figure 1A).
No association was observed in relation to previous treatment
with chemo-immunotherapy (Figure S2).
Amongst patients treated with ibrutinib [median 21 months
(range 6–32)] the CD3+ T cell count was substantially reduced
[median 1,154 cells/µl to 216 cells/µl; (p = 0.013)] and the
CD8+ T cell count also decreased markedly from median 515
cells/µl to 104 cells/µl; (p = 0.011). As expected, the total
lymphocyte count fell from 25 to 3.4× 109/l during the treatment
period (Figure 1A).
Interestingly the use of ibrutinib was associated with a
reduction in PD-1 expression on CD8+ T cells [28% pre-
treatment vs. 24.6% (p = 0.042)]. In addition, patients who
reached a complete response (CR) as defined by IWCLL criteria,
had a greater delta change in their PD-1 expression compared to
those obtaining a partial response (−0.25 vs. −0.03; p = 0.043)
(11). Patients who achieved a CR with ibrutinib treatment,
also tended to have a lower frequency of PD-1 CD8+ T cells
prior to commencing therapy, although this did not reach
statistical significance (24.05 vs. 35.3%; p = 0.130). Importantly
the duration of ibrutinib therapy was not found to differ between
patients who achieved PR compared to those reaching a CR (23.5
vs. 21 months, respectively; p= 0.924) and no difference was seen
in expression of other inhibitory markers that are increased in
patients with CLL (1) (CD244 (52 vs. 55%; p= 0.426), CD160 (25
vs. 23%; p = 0.326), or CTLA4 expression (3.05 vs. 2.55%; p =
0.622) (Figure 1B).
We next went on to examine the functional activity of T
cells and initially stimulated PMBC with PMA and ionomycin
mitogen. Serial samples from patients on ibrutinib exhibited a 3.5
fold increase during therapy in the proportion of CD8+T cells
that produced TNFα and INFγ following mitogenic stimulation
[TNFα 13.1–45.7% (p= 0.013); IFNγ 12.4–44.7% (p= 0.0215) n
= 13] (Figure 1C). However, the absolute number of cytokine-
positive CD8+ T cells remained unchanged [pre-treatment
IFNγ producing CD8+ T cells: 144 vs. 311 cells/µL during
ibrutinib (p = 0.07) and TNFα producing CD8+ T cells: 147
pre-treatment vs. 306 cells/µL during ibrutinib (p = 0.09)]
suggesting that long-term ibrutinib therapy acts to reduce the
frequency of hypofunctional T cells. To address the impact
of ibrutinib on T cell cytotoxicity, PBMCS were incubated
with a T cell stimulation cocktail and CD107a degranulation
assessed. Although no statistical difference in the frequency of
response was noted, a trend towards increased CD107a release
was observed with therapy [pre-ibrutinib 11.1% vs. 24.2% during
ibrutinib (p = 0.485; n = 4)]. To assess if ibrutinib therapy
impacted on the memory status of CD8+ T cells, a comparison
was made before and during therapy. However, no difference
in the frequency of memory cell subsets of CD8+ T cells
was found (2 way Anova of repeating measures p = 0.998;
n= 4) (Figure 1D).
The impact of ibrutinib on antigen-specific immune responses
was next investigated through the use of HLA-peptide tetramer
staining and viral peptide stimulation. Donor CMV and EBV
serostatus and HLA genotype was first determined. Following
incubation overnight with pooled CMV or EBV peptide, CD8+
T cell release of CD107a was assessed and compared between
samples taken before and during ibrutinib therapy. No difference
was observed in the release of CD107a following antigen
stimulation [21.34% before therapy vs. 22.16% during therapy
(p= 0.879)].
Next, the appropriate HLA class I tetramer staining of PBMC
was combined with surface membrane immunophenotyping.
PD-1 expression on CMV-specific CD8+ T cells was not found
to be modulated by ibrutinib therapy (12.6 vs. 11.1%; data not
shown) suggesting that CMV-specific CD8+ T cells do not
account for the reduced frequency of PD-1 positive cells observed
in the total CD8+ T cell population. However, paired PBMC
samples showed an increased frequency of cytokine production
with BTKi treatment following CMV-peptide pool stimulation
[IFNγ: 0.46–0.78% (p = 0.048) and TNFα: 0.69–1.05% (p =
0.274)] (Figure 2A). The frequency of cytokines produced by
EBV-specific CD8+ T cells also increased [TNFα: 0.85–1.81%
(p = 0.047) and IFNγ 0.63 vs. 2.34% (p = 0.219)] (Figure 2A).
Despite this, no difference was found in their absolute number
before and during ibrutinib therapy [CMV peptide stimulation:
(IFNγ: 5.6 vs. 5.8 cells/µL (p= 0.56); TNFα 2.2 vs. 3.7 cells/µL (p
= 0.3) and EBV peptide stimulation: IFNγ: 0.85 vs. 1.8 cells/µL
(p = 0.05); TNFα 0.63 vs. 3.2 cells/µL (p = 0.22)]. This indicates
that the frequency but not absolute number of hypofunctional
EBV or CMV-specific CD8+ T cells is reduced during
ibrutinib therapy.
We were further interested to see if this improved functional
activity might lead to a reduction in the number of virus-specific
T cells. Indeed, HLA-peptide tetramer staining showed that the
median frequency of CMV-specific T cells fell from 1.7% of the
CD8+ repertoire before ibrutinib to 1.1% during therapy (p <
0.05; n = 7). Similarly, EBV-specific responses were also reduced
by over 50% (4.2% pre-ibrutinib vs. 1.9% during therapy; n = 6)
(Figures 2B,C).
DISCUSSION
Ibrutinib has transformed the management of CLL and many
patients have now been on continuous therapy for many
years. However, despite proven efficacy in suppression of B
cell lymphoproliferation little is known regarding the impact
of ibrutinib on immune function. Our analysis determined the
impact of ibrutinib on antigen-specific T cells for the first time
and also assessed patients with the longest treatment duration to
date (9).
The striking reduction in CD3+ and CD8+ T cell number
during ibrutinib therapy has been observed previously (12). In
contrast Long et al. noted that the total CD8+ T cell response
actually increased during ibrutinib therapy but this was within
the first 6 months of therapy, when the absolute lymphocyte
count was almost double the initial pre-treatment lymphocyte
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FIGURE 1 | Long term ibrutinib therapy decreases PD-1 expression on CD8+ T cells and increases the functional response to mitogen stimulation. (A) PD-1
expression on CD8+ T cells was ascertained using flow cytometry. An increased frequency of PD-1 expression was observed amongst untreated patients and those
(Continued)
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FIGURE 1 | treated with chemo-immunotherapy only (n = 65), compared to healthy donors (n = 19). A reduction in the absolute number of both CD3+ and CD8+ T
cells was observed during long term ibrutinib therapy. (B) The frequency of expression of checkpoint receptors on CD8+ T cells of 14 patients with relapsed refractory
CLL treated with ibrutinib is shown over the treatment duration, including (i) PD-1, (ii) CD160, (iii) CD244, and (iv) CTLA4). A decreased percentage of PD-1 positive
CD8+ T cells was observed in the patients with CLL during long-term ibrutinib therapy. (C) PBMCs from 13 patients with CLL were stimulated with PMA plus
ionomycin, before and during ibrutinib therapy. The CD8+ T cells producing IFNγ and TNFα were identified through intracellular staining and flow cytometric analysis
and an increased frequency of both cytokine-producing CD8+ T cells were found in B-CLL patients during ibrutinib therapy. (D) Memory subset analysis was
performed using CCR7 and CD45RA to define naïve, central memory (CM), effector memory (EM), and TEMRA CD8+ T cell populations. No difference in the frequency
of the subsets of memory cells was found before or during ibrutinib therapy (n = 4).
FIGURE 2 | Long term ibrutinib therapy decreases the frequency of virus-specific CD8+ T cells and improves the functional response to stimulation with viral peptides.
PBMCs from patients with CLL were stimulated with pooled CMV and EBV peptides. The CD8+ T cells producing IFNγ and TNFα were identified through intracellular
staining and flow cytometric analysis. The percentage of cytokine producing CD8+ T cells were compared between patients before and during ibrutinib therapy. (A) (i)
With pooled CMV peptide stimulation, significantly increased frequencies of IFNγ producing CD8+ T cells were found in patients with CLL during ibrutinib therapy (p =
0.048). (ii) With pooled EBV peptide stimulation, significantly increased frequencies of TNFα producing CD8+ T cells were found in patients during ibrutinib therapy (p
= 0.047). (B) An example of the flow cytometric plot of EBV tetramer staining is shown, demonstrating the reduced frequency of EBV specific CD8+ T cells during
ibrutinib therapy. (C) The frequency of CMV specific CD8+ T cells and EBV-specific CD8+ T cells in B-CLL patients before and during ibrutinib therapy were
compared. The frequencies of both virus-specific cells decreased during ibrutinib treatment in B-CLL patients (p = 0.046 for CMV and p = 0.03 for EBV).
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count. The difference observed between this work and the work
of Long et al., may reflect a difference in the duration of
ibrutinib therapy as similarly to our findings, Niemann et al.
reported a reduction in T cell numbers by week 48 of ibrutinib
treatment (13). Increased expression of PD-1 on CD8+ T cells
is a characteristic feature of patients with CLL and predicts
progression risk (1, 3). Importantly, long-term ibrutinib therapy
reduced PD-1 expression on CD8+ T cells and this effect
was not observed following conventional chemotherapy. An
intriguing observation was that the reduction in PD-1 expression
was more pronounced in patients who went on to achieve a
complete remission in response to ibrutinib therapy and this
group also exhibited a trend towards a lower overall percentage
of PD-1+ CD8+ T cells prior to therapy. It is currently
unclear if this correlation reflects a secondary improvement in
immune function within individuals who gain excellent clinical
responses to ibrutinib or if reversal of T cell exhaustion may
itself play a role in mediating the therapeutic response to
ibrutinib treatment.
The expression of additional checkpoint proteins was not
modulated by ibrutinib therapy. Expression of intracellular
CTLA4 has previously been reported to decrease with ibrutinib
therapy, whereas our analysis assessed surface expression staining
(10). PD-1 is a defining phenotypic feature of T cell exhaustion
and we observed increased cytokine responses within CD8+
cells following long-term ibrutinib therapy indicating that BTK
inhibition also reverses features of functional exhaustion. This
may be achieved partly through suppression of the CLL clone,
which shares features with B regulatory cells and correction of a
range of elevated cytokines is observed within the first 2 months
of ibrutinib therapy (12, 14). Further mechanisms for reversal of
T cell exhaustion may include a reduction in chronic antigenic
stimulation both from the decrease in tumour load and improved
immune competence against infective agents.
To evaluate the latter we focused on the immune response
to latent herpesviruses, which drive expanded CD8+ T
cell responses in CLL in a mechanism that is thought to
reflect a response to increased endogenous viral replication.
EBV infection is associated with accelerated time to disease
progression in CLL (15) althoughCMVhas no known deleterious
effect (16). Of interest, the magnitude of CD8+T cell CMV-
specific responses increased with advanced stage disease, in line
with a previous study of CD4+ immunity (data not shown)
(17). Importantly, the magnitude of the virus-specific immune
responses reduced during ibrutinib therapy, with a comparable
increase in peptide-specific cytokine responses. These findings
are the first report of improvement in antigen-specific immune
responses following ibrutinib therapy. The proportion of PD-1+
CMV-specific T cells was not influenced by ibrutinib therapy,
despite a decrease in the global PD-1+ CD8+ pool, indicating
that reversal of T cell exhaustionmay be directed towards tumour
specific T cell responses. This also suggests that PD-1 is not
contributing to the improvement in antigen-immune response
observed in virus-specific T cells. Indeed, previous published
work found a normal cytokine response in CMV-specific CD8+
T cells in patients with CLL, when CMV peptide was presented
via lymphoblastoid cell lines or healthy donor B cells and in a
controlled B: T cell ratio. In contrast, cytokine responses were
impaired when CMV peptide was presented via CLL cells. The
improvement observed in herpes-virus specific T cells in this
study may therefore relate to the reduction in the CLL clone,
rather than the expression of PD-1 (18).
Inducible T cell kinase (ITK) plays an important role in the
maintenance of Th2 CD4+ cells and memory CD8+ T cells
and is known to be inhibited by ibrutinib (5). However, Itk−/−
CD8+ memory T cells (in comparison to naïve CD8+ T cells)
demonstrate normal recall responses to bacterial infection in
terms of frequency and functionality and this is compatible with
our findings (19). The impact of ibrutinib on the induction of
primary immune responses mediated by naïve T cells deserves
further investigation. Ibrutinib has previously been associated
with improvements in T cell function including an increase
the degree of diversity within the T cell repertoire (14) and
enhanced outcome of CAR-T therapy in patients with CLL
(20). Our findings now demonstrate a reversal in the degree of
phenotypic and functional exhaustion and help to explain the
encouraging clinical experience of BTKi therapy in relation to
infection risk (21).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, to any
qualified researcher.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Ethical approval was obtained from West Midlands
regional ethics committee for patients (10/H1206/58) and for
healthy donor controls (2002/073). The patients/participants
provided their written informed consent to participate in
this study.
AUTHOR CONTRIBUTIONS
HP and HL designed the research. HP, NM, JB, NC, JZ, MK,
and CO conducted the experiments. CH performed statistical
analysis. SP,MK, and TM recruited patients and followed patients
up. HP, GP, TS, and PM wrote the manuscript.
FUNDING
This work was funded by The Wellcome Trust and open access
publication fees from The University of Birmingham.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.02832/full#supplementary-material
Frontiers in Immunology | www.frontiersin.org 6 December 2019 | Volume 10 | Article 2832
Parry et al. Ibrutinib Reverses T-Cell Exhaustion
REFERENCES
1. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S,
et al. T cells from CLL patients exhibit features of T-cell exhaustion
but retain capacity for cytokine production. Blood. (2013) 121:1612–21.
doi: 10.1182/blood-2012-09-457531
2. Mackus WJM, Frakking FNJ, Grummels A, Gamadia LE, De Bree GJ,
Hamann D, et al. Expansion of CMV-specific CD8+CD45RA+CD27- T
cells in B-cell chronic lymphocytic leukemia. Blood. (2003) 102:1057–63.
doi: 10.1182/blood-2003-01-0182
3. Nunes CT, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a
CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is
associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer
Res. (2011) 18:678–87. doi: 10.1158/1078-0432.CCR-11-2630
4. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N
Engl J Med. (2013) 369:32–42. doi: 10.1056/NEJMoa1215637
5. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong
Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving
a Th1-selective pressure in T lymphocytes. Blood. (2013) 122:2539–49.
doi: 10.1182/blood-2013-06-507947
6. Wherry EJ. T cell exhaustion. Nat Immunol. (2011) 12:492–9.
doi: 10.1038/ni.2035
7. Kilgour AH, Firth C, Harrison R, Moss P, Bastin ME, Wardlaw JM,
et al. Seropositivity for CMV and IL-6 levels are associated with grip
strength and muscle size in the elderly. Immun Ageing. (2013) 10:33.
doi: 10.1186/1742-4933-10-33
8. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr
virus carrier state in healthy seropositive individuals. Int J Cancer. (1985)
35:35–42. doi: 10.1002/ijc.2910350107
9. Bunce M, O’Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris
PJ, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C,
DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes
utilizing sequence-specific primers (PCR-SSP). Tissue Antig. (1995) 46:355–
67. doi: 10.1111/j.1399-0039.1995.tb03127.x
10. Pachnio A, Begum J, Fox A, Moss P. Acyclovir therapy reduces the
CD4+ T cell response against the immunodominant pp65 protein from
cytomegalovirus in immune competent individuals. PLoS ONE. (2015)
10:e0125287. doi: 10.1371/journal.pone.0125287
11. Hallek M, Cheson BD, Catovsky D, Caligaris-cappio F, Dighiero G, Dohner
H, et al. IWCLL guidelines for diagnosis, indications for treatment, response
assessment, and supportive mangement of CLL. Blood. (2018) 131:2745–60.
doi: 10.1182/blood-2017-09-806398
12. Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A,
Chang BY, et al. Disruption of in vivo chronic lymphocytic leukemia
tumor-microenvironment interactions by ibrutinib–findings from an
investigator-initiated phase II study. Clin Cancer Res. (2016) 22:1572–82.
doi: 10.1158/1078-0432.CCR-15-1965
13. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM,
et al. Ibrutinib treatment improves T cell number and function in
CLL patients. J Clin Invest. (2017) 127:3052–64. doi: 10.1172/JCI
89756
14. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O’Brien S, et al.
Ibrutinib therapy increases T cell repertoire diversity in patients
with chronic lymphocytic leukemia. J Immunol. (2017) 198:1740–7.
doi: 10.4049/jimmunol.1601190
15. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, et al. Epstein-
barr virus MicroRNAs are expressed in patients with chronic lymphocytic
leukemia and correlate with overall survival. EBioMedicine. (2015) 2:572–82.
doi: 10.1016/j.ebiom.2015.04.018
16. Parry HM, Damery S, Hudson C, Maurer MJ, Cerhan JR, Pachnio A, et al.
Cytomegalovirus infection does not impact on survival or time to first
treatment in patients with Chronic Lymphocytic Leukaemia. Am J Hematol.
(2016) 91:776–81. doi: 10.1002/ajh.24403
17. Pourgheysari B, Bruton R, Parry H, Billingham L, Fegan C, Murray J,
et al. The number of cytomegalovirus-specific CD4+ T cells is markedly
expanded in patients with B-cell chronic lymphocytic leukemia and
determines the total CD4+ T-cell repertoire. Blood. (2010) 116:2968–74.
doi: 10.1182/blood-2009-12-257147
18. te Raa GD, Pascutti MF, Garcia-vallejo JJ, Reinen E, Remmerswaal
EB, ten Berge IJ, et al. CMV-specific CD8+ T c-cell function is not
impaired in chronic lymphocytic leukaemia. Blood. (2014) 123:717–24.
doi: 10.1182/blood-2013-08-518183
19. Huang F, Huang W, Briggs J, Chew T, Bai Y, Deol S, et al. The tyrosine kinase
Itk suppresses CD8+ memory T cell development in response to bacterial
infection. Sci Rep. (2015) 5:7688. doi: 10.1038/srep07688
20. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al.
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy
in leukemia. Blood. (2016) 127:1117–27. doi: 10.1182/blood-2015-11-679134
21. Williams AM, Baran AM,Meacham PJ, FeldmanMM, Valencia HE, Newsom-
Stewart C, et al. Analysis of the risk of infection in patients with chronic
lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma. (2018)
2017:1–8. doi: 10.1080/10428194.2017.1347931
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Parry, Mirajkar, Cutmore, Zuo, Long, Kwok, Oldrieve, Hudson,
Stankovic, Paneesha, Kelly, Begum, McSkeane, Pratt and Moss. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Immunology | www.frontiersin.org 7 December 2019 | Volume 10 | Article 2832
